The effect of butylscopolamine on [ 18 F]FDG uptake in the gastrointestinal tract is negligible and regionally variable.

Butylscopolamine reduces gastrointestinal FDG accumulation only in selected segments and, despite a significant effect, only to a small extent. A general recommendation for the use of butylscopolamine cannot be derived from these results, its use for specific issues could be considered individually.